A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
Clinical Trial Grant
Awarded By
Mirati Therapeutics, Inc.
Start Date
July 9, 2019
End Date
May 23, 2024
Awarded By
Mirati Therapeutics, Inc.
Start Date
July 9, 2019
End Date
May 23, 2024